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Abstract 
Amine transaminases are important biocatalysts for the synthesis of chiral primary amines. 
Unlike many enzymes that have been employed for the synthesis of optically active amines, 
amine transaminases are capable of asymmetric synthesis and do not rely on costly 
cofactors that must be regenerated in situ. However, their application as general catalysts for 
the preparation of amines is hampered by a limited substrate scope, substrate and 
(co)product inhibition and difficulties associated with displacing challenging reaction 
equilibrium. There has been important progress made to overcome these challenges, 
including the development of enzymes with broader substrate scope and the design of 
methodology to effectively displace the reaction equilibrium. Amine transaminases are also 
being applied in an increasing range of (chemo)enzymatic cascades and immobilized for 
applications in flow.  
 
 
Introduction 
Chiral amines are prevalent in active pharmaceutical ingredients, agrochemicals and 
bioactive natural products and are important pharmaceutical building blocks. As such, the 
development of broadly applicable biocatalytic strategies for their synthesis is of great 
interest. A number of enzymes have been employed for the synthesis of chiral amines, 
including transaminases, amine dehydrogenases, imine reductases, ammonia lyases, 
monoamine oxidases [1] and the more recently discovered reductive aminase [2**] (Figure 
1). Transaminases (TAs) belong to fold types I and IV of pyridoxal 5’-phosphate (PLP) 
dependent enzymes and catalyse the reversible transfer of an amino group from a suitable 
donor to a carbonyl acceptor. Two types of PLP-dependent TAs have been identified and 
are grouped according to the type of substrate they convert [3]. α-TAs exclusively convert α-
amino and α-keto acids whereas ω-TAs can accept substrates with a distal carboxylate 
group. Importantly, a subgroup of ω-TAs, known as amine TAs (ATAs) are capable of 
accepting substrates that completely lack a carboxylate group and these enzymes have 
received considerable attention in recent years due to their potential for the synthesis of 
chiral primary amines from the corresponding prochiral ketones.  
 
Despite the enormous potential of ATAs, challenges associated with substrate and co-
product inhibition, difficulties displacing reaction equilibria and substrate restrictions have 
contributed to their slow uptake by both the academic and industrial communities. There are 
a number of research groups addressing these challenges through enzyme engineering and 
process development and this review will focus on the most significant developments in the 
field over the past two years.  
 
 
 Figure 1. A selection of enzymes that can be used for the synthesis of chiral amines 
 
Expanding their substrate scope  
The substrate scope of ATAs can be considered relatively broad, as they are capable of 
catalysing the amination of a wide range of aldehydes and ketones. However, the active site 
of these enzymes contains a small and large binding pocket and therefore wild-type 
enzymes are restricted to ketones bearing at least one ‘small’ substituent (methyl or ethyl 
typically). Considerable effort has been directed towards increasing the capacity of the small 
binding pocket to enable these enzymes to accept ketones with two bulky substituents. The 
most high-profile example of such an engineering effort was reported in 2010, where an 
evolved (R)-selective ω-TA replaced a rhodium-catalysed hydrogenation step in the 
conversion of bulky ketone 1 (Figure 2) to the anti-diabetic drug, Sitagliptin [4]. The 
biocatalytic route offers dramatic improvements in yield, purity and selectivity compared to 
the traditional metal-catalysed approach and this landmark example has inspired 
subsequent engineering projects (Figure 2). Bornscheuer and co-workers have made 
substantial progress towards developing ATAs that accept substrates with two sterically 
demanding substituents. They recently reported an (S)-selective ω-TA variant from Ruegeria 
sp. TM1040 (3FCR) that is capable of converting bulky ketones (including 2 and 3) to the 
corresponding chiral amines with good to excellent yields and enantiomeric excess [5**]. 
Interestingly, the variant contains only four mutations and the approach has been shown to 
be transferrable to other fold class I ω-TA templates with similar sequence identities. Despite 
the impressive activity of this variant towards bulky substrates, relatively modest substituent 
changes are not tolerated well by the mutant and this highlights the challenges associated 
with developing TAs with broad activity. Additionally, the variants have not been shown to 
work effectively at high concentrations. The ATA from Ruegeria sp. TM1040 has also been 
engineered to accept the sterically demanding bridged ketone, exo-3-amino-8-aza-
bicyclo[3.2.1]oct-8-yl-phenylmethanone 4 [6], and variants of an AT from Vibrio fluvialis 
(PDB-ID: 4E3Q) showed activity towards branched-chain bulky-bulky ketones [7]. Moody 
and co-workers also developed a variant of 43EQ capable of mediating the conversion of the 
bulky substrate, 2-acetylbiphenyl 5, having identified no residual activity in the wild-type 
enzyme [8]. Targeting mutations in the small binding pocket to increase capacity is not the 
only effective approach. Shin and co-workers reported that mutation of the L57 residue in the 
large binding pocket of a TA from Ochrobactrum anthropi dramatically enhanced activity 
towards bulky arylalkylamines and alkylamines [9].  
 
 
Figure 2. Engineered ATAs that act on bulky substrates 1-5 [4,5,6,8] 
 
Displacing reaction equilibria  
A significant obstacle to the application of TAs for the synthesis of chiral amines is the 
reversible nature of the enzymatic reaction [10]. Achieving good conversion of ketone to 
amine requires removal of the carbonyl co-product in order to prevent the reverse reaction 
from competing and compromising conversion/yield (Figure 3) [11]. The most common 
amine donors employed are alanine and isopropyl amine, leading to pyruvate and acetone 
co-products. While there are well established methods for pyruvate removal, high 
equivalents of alanine in combination with complex and expensive co-product 
removal/recycling strategies are necessary. Isopropyl amine must also be employed in high 
concentrations and the acetone co-product removed in situ to achieve good conversions with 
challenging substrates and this often requires the use of engineered enzymes that can 
tolerate high substrate loadings. As neither of these strategies can be considered ideal, 
there have been a number of studies focused on developing novel methodology for 
displacing the reaction equilibrium effectively.   
Berglund and co-workers reported the application of 3-aminocyclohexa-1,5-dienecarboxylic 
acid as a TA amine donor [12]. The resulting ketone co-product is highly unstable and 
tautomerises to give the more stable isomer, 3-hydroxybenzoic acid. While this effectively 
displaces the reaction equilibrium, the amine donor is not easily accessible and therefore its 
practical use is limited. Our group have an ongoing interest in the development of ‘smart’ 
amine donors and recently demonstrated that commercially available o-xylylenediamine can 
be employed in combination with some of the most widely used ATAs and enables high 
conversions to be achieved with challenging ketone substrates [13]. Additionally, the black 
polymer co-product formed means that the methodology also enables effective high-
throughput screening. As this amine donor is expensive and unlikely to be employed for 
large-scale industrial synthesis the methodology has been extended to include other smart 
diamine donors and has recently been shown to work with a number of ATAs [14,15].  
The amines cis-1,4-but-2-ene-diamine and trans-1,4-but-2-ene-diamine have also been 
shown to shift the reaction equilibria of TA reactions via cyclization and tautomerization of 
their co-products [16]. Kroutil and co-workers assessed a small panel of 1,2-diamines that 
were expected to spontaneously dimerize and oxidize to form a stable co-product [17]. 
However, the slow dimerization limits the utility of these donors and the methodology has not 
been shown to work effectively with challenging ketones.  
 
 Figure 3. Selected examples of strategies to displace the reaction equilibria of TA reactions 
 
Continuous flow biotransformations 
The application of enzymes in continuous flow is not a recent development, yet there have 
been limited examples of the use of ATAs. Optimized biotransformations in flow are 
particularly attractive for large scale reactions as they are typically more reproducible, able to 
tolerate substrates with low solubility and are significantly more productive and economic 
than those performed in batch. Effective enzyme immobilization is an essential component of 
successful flow biotransformations and there have been a number of strategies recently 
reported for TAs.  
Whole E. coli cells expressing an (R)-selective ω-TA from Arthrobacter have been 
immobilized on methacrylate beads and biotransformations performed in organic solvent to 
minimize leaching of both the enzyme and PLP co-enzyme [18]. This system allowed the 
synthesis of a number of α-alkoxy- and α-aryloxy acetone derivatives with good conversions 
and yields. Paradisi and co-workers immobilized an interesting wild-type ATA (HEWT) from 
the moderate halophile Halomonas elongate on epoxy Sepabeads [19]. The enzyme was 
capable of transforming a series of aldehydes to the corresponding amine in excellent 
conversion and isolated yield. Most impressive was the rapid reaction time and high 
conversions achieved compared to those performed in batch. For example, the system 
allowed for complete conversion of para-nitro-benzaldehyde to para-nitro-benzylamine in 2 
minutes under flow conditions whereas the corresponding batch conditions took 210 minutes 
to achieve the same conversion.   
An interesting article has recently been reported where the authors demonstrate a strategy 
for the dynamic ionic absorption of phosphorylated co-factors (PLP and NADH) on a porous 
material [20]. The authors demonstrated that a transamination (and asymmetric reduction of 
a ketone with ADH/NADH) can be performed without the need for externally supplied PLP, 
due to the co-enzyme shifting from an associated to disassociated state without being 
leached into the bulk aqueous media. The authors chose the kinetic resolution of Rac-
methylbenzylamine to showcase their methodology rather than an asymmetric biocatalytic 
transamination and therefore it remains to be seen how well the system would perform for 
the asymmetric synthesis of chiral amines.  
Sans and co-workers have recently demonstrated the first example of modified 3D printed 
devices for the immobilization and application of enzymes in continuous-flow [21]. The 
authors use the benchmark conversion of (S)- and (R)-methylbenzylamine to acetophenone 
in the presence of pyruvate, using both (S)- and (R)-selective ATAs to showcase the 
technology. The approach has the potential to enable rapid screening of immobilization 
strategies and reaction conditions that can be easily transferred to large-scale continuous 
flow bioreactors. 
 
Application in synthesis 
Lipases have relatively broad substrate scope and predictable activity, and can be 
successfully applied for efficient kinetic resolution chemistry. For these reasons, they have 
secured their place in synthetic chemistry laboratories in both academia and industry [22]. In 
recent years, there has also been increased interest from industry in the application of TAs 
for the synthesis of chiral amines.  
Researchers at Pfizer reported a chemo-enzymatic route for the synthesis of key chiral 
intermediates of a gamma secretase inhibitor with potential anti-tumour activity, employing a 
transaminase and an alcohol dehydrogenase (Scheme 1c) [23]. ATA-47 from CLecta was 
selected following the screening of a relatively large enzyme library and the team 
demonstrated that they could employ the enzyme for the conversion of a substituted 
tetralone to the corresponding (S)-amine with excellent selectivity. An impressive feature of 
the work was the large scale at which the reaction was performed (24.8 Kg of 6,8-
difluorotetralone), enabling the preparation of almost 40 Kg of material, in 94% isolated yield.  
The HEC pharm group reported the application of an (R)-selective ATA for the synthesis of 
pharmaceutically relevant (3R)-3-aminoazepane [24], which is an important motif in a class of 
epidermal growth factor receptor antagonists that were developed at Novartis. This challenging 
substrate required extensive reaction optimisation to afford a good yield but the inclusion of the 
biocatalytic step resulted in a simplified reaction work-up, circumvented the need for precious 
metal catalysts and provided the desired chiral amine with excellent stereoselectivity.  
 
There have been some recent examples of performing ATA reactions on a preparative scale to 
access chiral primary amines [25, 26] and a handful where the enzyme is employed to synthesise 
more complex chiral targets, which highlight their potential for multi-step synthesis. The Natural 
product (+)-xenovenine and its isomer were synthesised via a chemoenzymatic approach 
involving a key ATA-mediated amination of tricarbonyl 6 (Scheme 1a) [27]. As expected, the 
enzyme was completely selective for the methyl ketone and spontaneously cyclised afforded 
cyclic imine 7, which was subsequently converted to the target compound 8 in two further 
steps. Ryan et. al. recently reported the preparative-scale synthesis of a series of chiral 
piperidines, starting from easily accessible pro-chiral ketoenones [28*]. Following 
transamination, a spontaneous thermodynamically favourable aza-Michael type reaction 
occurs and means that only two equivalents of isopropylamine are required to achieve 
excellent conversions and isolated yields. The work also highlights an interesting example of 
how the reversibility of the biocatalytic reaction negates the need for regio-selectivity in the 
Synthesis of the natural product, (-)-pinidinone 10, starting from dimethyl ketoenone 9 
(Scheme 1b) highlights an interesting example of how the reversibility of the biocatalytic 
reaction negates the need for regio-selectivity and can be exploited to shuttle the amine 
across the molecular framework. 
 
 Scheme 1. Selected examples of TAs being applied for the synthesis of more 
complex products [23, 27, 28] 
 
Biocatalytic cascades 
Enzymatic cascades involving the combination of several concurrent biocatalytic steps in 
one-pot can enable access to complex chiral molecules starting from simple building blocks 
and avoids the need for costly intermediate purification steps or protecting group 
manipulations. There have been a number of recent reports of biocatalytic cascades 
involving TAs in combination with aldolases [29, 30], laccases [31], transketolases [32], 
pictet-spenglerase [33], alcohol dehydrogenases [34*, 35*, 36], acyl transferases [37] and 
ene-reductases [38].  
An elegant three enzyme cascade has recently been reported for the synthesis of mono- and 
di-substituted piperidines and pyrrolidines starting from keto acids, by applying a carboxylic 
acid reductase (CAR), an ω-TA and an imine reductase (IRED) in one-pot [39]. The strategy 
relies on the selectivity of the commercially available TA (ATA113 from codexis) for the 
aldehyde over the bulky ketone. Subsequent IRED-mediated reduction of the imine afforded 
the product piperidines or pyrrolidines. The cascade was also performed in a whole-cell 
system by Flitsch and co-workers [40].  
Both et. al. reported an impressive whole-cell biocatalytic cascade for the conversion of 4-
substituted ethylbenzenes to 4-substituted phenylethylamines [34*]. The strategy relied on 
four heterologously expressed enzymes to achieve the transformation, with the required co-
factors also supplied by the host. A catalytically self-sufficient cytochrome P450 
monooxygenase generated a benzylic alcohol, which was subsequently oxidised to the 
corresponding ketone using an alcohol dehydrogenase (ADH). Two stereo-complementary 
ADHs where expressed to ensure complete oxidation in the event of poor selectivity in the 
oxidation step. Finally, ATA117 from Arthrobacter sp catalysed a highly selective 
transamination to afford the 4-substituted (R)-phenylethylamines in excellent e.e. and 
extremely impressive isolated yield.  
An outstanding example of a multi-enzyme whole-cell cascade has recently been reported 
using up to eight carefully selected enzymes, including styrene monooxygenase, epoxide 
hydrolase, alcohol dehydrogenase and catalase, for the conversion of styrenes to 
substituted amino alcohols and amino acids with surprisingly high conversions achieved 
[35*].  
As the substrate scope of ATAs expand, there will be further opportunities to apply them in 
cascade reactions for the synthesis of complex molecules with multiple stereocentres.  
 
 
Conclusions 
Despite the growing ‘toolbox’ of enzymes available for biocatalytic amine synthesis, TAs 
continue to fill an important role for the asymmetric preparation of chiral primary amines. The 
application of an engineered TA for the industrial synthesis of sitagliptin [4] demonstrates the 
power and efficiency of chemo-enzymatic synthesis using these important biocatalysts. 
However, while there has been significant progress made towards expanding the substrate 
scope of TAs and developing strategies to displace the challenging reaction equilibria, the 
vast majority of enzymes still lack suitably broad substrate scope and activity and are thus 
unlikely to be considered as routine catalysts for synthetic chemistry applications. It is 
necessary to address the challenge of substrate and (co)product inhibition and develop TAs 
that are not restricted to narrow substrate sets, before these enzymes can start to truly 
impact on synthetic design strategies and be considered alongside more traditional chemical 
catalysis [41]. 
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